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Objective: Evidence suggests prolonged exposure to lower levels of low-density lipoprotein
cholesterol (LDL-C), starting at a younger age, substantially lowers cardiovascular (CV) risk.
Accordingly, the CV pandemic affecting younger population in low- to low-middle-income coun-
tries, where statin usage is poor even in secondary prevention, may beneﬁt from lipid-lowering
nutritional products, as nutritional intervention is generally preferred in these cultures. Howev-
er, the safety and efﬁcacy of such preparations have not been systematically tested.
Methods: In this multicenter, double-blind study, 191 statin-free subjects with newly-diagnosed
hyperlipidemia (LDL-C >120 mg/dL, 3.11 mmol/L) and no evidence of CV disease were random-
ized to one capsule of a proprietary bioactive phytonutrient formulation containing red yeast rice,
grape-seed, niacinamide, and folic acid (RYR-NS) or matched placebo twice daily, along with
lifestyle modiﬁcation, for 12 wk.
Results: Mean baseline LDL-C levels were 148.5  24.0 mg/dL (3.85  0.62 mmol/L) and
148.6  21.9 mg/dL (3.85  0.57 mmol/L) in the RYR-NS and placebo groups respectively. Compared
withplacebo,RYR-NS resulted ina signiﬁcant reduction inLDL-C (29.4%versus3.5%,P<0.0001)and
non–high-density lipoprotein cholesterol (non-HDL-C; 29.8% versus 10.3%, P < 0.0001) at 12 wk.
With RYR-NS, 43.4% individuals attained desirable LDL-C levels and 55.4% desirable non-HDL-C levels
by week 12, compared to only 0% and 1.1%, respectively, at baseline. No safety issues were observed.
Conclusion: This study demonstrates the efﬁcacy and safety of RYR-NS in lowering LDL-C and non-
HDL-C after 12 wk, with magnitude of LDL-C reduction being comparable to that seen with
moderate-intensity statin therapy. Further long-term studies are required to determine the impact
of RYR-NS on treatment adherence and clinical outcomes.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t. Ltd., Chennai, India, for
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increasing evidence also suggests that the duration of exposureThe cardiovascular (CV) disease (CVD) pandemic has led to an
unprecedented increase in morbidity and mortality, especially in
low- and lower-middle-income countries [1,2]. In these pop-
ulations, a higher prevalence of CVD risk factors at a younger age
coupled with genetic predisposition are the predominant rea-
sons for the rapidly increasing CVD burden [3]. Of the major CVD
risk factors, dyslipidemia remains the single-most important
factor because of its high prevalence and direct pathogenic as-
sociation with atherosclerosis [4].
Large-scale epidemiologic and clinical studies have shown
that lowering of low-density lipoprotein cholesterol (LDL-C)
levels through pharmacologic and/or non-pharmacologic means
is associated with signiﬁcant CV beneﬁts, with each mmol/L
reduction in LDL-C levels leading to an approximately 30%
reduction in the risk of adverse CV events [5–10]. These bene-
ﬁcial effects of LDL-C reduction are seen irrespective of theFig. 1. CONSORT diagram depicting ﬂow of the patients throto low LDL-C levels may be as important as the magnitude of
LDL-C lowering [11–16]. A large meta-analysis by Ference et al.
has demonstrated that prolonged exposure to lower LDL-C
levels beginning at a young age is associated with a substan-
tially greater reduction in the risk of CVD than the current
practice of lowering LDL-C levels later in life [13]. At the same
time, convincing data is also available to demonstrate the safety
of very low LDL-C levels [17–19]. These evidences together
suggest that the effectiveness of LDL-C lowering for primary
prevention of CVD can be potentially and substantially
improved by initiating LDL-C lowering therapies much earlier in
life than what is currently practiced. These observations are
particularly relevant for developing countries where CVD
epidemic is growing exponentially and the healthcare infra-
structure is grossly unequipped to manage the resultant
morbidity and mortality burden.ugh the trial. LDL-C, low density lipoprotein cholesterol.
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need for early and effective LDL-C lowering, the best approach to
achieve this is not clearly known. Although statins are the most
effective lipid-lowering agents with unequivocal CV risk reduc-
tion ability, their long-term usage generally remains poor, with
less than 5% of patients with a previous CV event continuing on
statin therapy beyond 5 y in low- and low-middle-income
countries [20]. Interestingly, the use of statins (and other
proven therapies) has been shown to be much lower in younger
individuals compared to the older ones [20], suggesting that the
concern of adverse effects and an inherent psychological barrier
against being on a “drug for life” are among themajor reasons for
such a low uptake of statins. These apprehensions are even
greater in primary prevention settings where long-term therapy
is required and the potential beneﬁts of the treatment are not
immediately apparent. In these circumstances, a food-derived
formulation that could safely and effectively lower LDL-C levels
could potentially lead to signiﬁcant public health beneﬁts by
being perceived as a “softer” therapeutic option and therefore
being culturallymore acceptable. However, while there are many
dietary supplements that claim to exhibit lipid-lowering efﬁcacy,
none are backed with the rigor of randomized, double-blind
clinical trial evidence. Therefore, this study was sought to eval-
uate lipid-lowering efﬁcacy and safety of RYR-NS, a proprietary
bioactive phytonutrient formulation containing red yeast rice
(RYR) powder, grapeseed powder, niacin, folic acid, and black
pepper seed powder (Appendix A). RYR has a mechanism of
action similar to that of statins [21–24], whereas niacin and
grapeseed powder are known to improve lipid proﬁle through
different mechanisms [25–27]. This formulation is currently
available under the brand name PreLipid (Prevention Meds, Inc,
Lebanon, NJ, USA). This study was performed as part of Evalua-
tion Series on Safety & Efﬁcacy of Nutritional Supplements
(ESSENS).
Methods
Study design
This was a multicenter, randomized, double-blinded, placebo controlled
study (Fig. 1) conducted at nine clinical sites across India (Appendix B). At all nine
sites, the study was approved by the respective institutional review boards andTable 1
Baseline clinical and biochemical characteristics of the study population
Parameters
Age, years
Male sex, n (%)
Body weight, kg
Diabetes, n (%)
Body mass index, kg/m2
Total cholesterol, mg/dL (mmol/L)
Low-density lipoprotein cholesterol, mg/dL (mmol/L)
High-density lipoprotein cholesterol, mg/dL (mmol/L)
Non-high density lipoprotein cholesterol, mg/dL (mmol/L)
Serum triglyceride, mg/dL (mmol/L)
Glycosylated hemoglobin, %
Blood urea nitrogen, mg/dL
Serum creatinine, mg/dL
Total bilirubin, mg/dL
Alanine transaminase, U/L
Aspartate transaminase, U/L
Alkaline phosphatase, U/L
Concomitant medications, n (%)
Angiotensin converting enzyme inhibitors/angiotensin receptor blockers
Beta-blockers
Oral hypoglycemic agentsthe local independent ethics committees. Written informed consent was ob-
tained from each participant before enrolment in the study. The ﬁrst patient was
enrolled on 10 March 2014 and the last patient’s ﬁnal visit took place on
November 2, 2014. The study was registered with Clinical Trials.Gov
(#NCT02187757).
Participants
Treatment-free patients ages 18 to 65 y with newly diagnosed hyperlipid-
emia (LDL-C>120mg/dL or 3.11mmol/L) were eligible to participate in the study.
We used a slightly lower cut-off of LDL-C than traditionally deﬁned (130mg/dL or
3.37 mmol/L), as Indians are known to have lower LDL-C levels than Western
populations [28,29]. Individuals with known CVD, uncontrolled blood pressure,
clinically signiﬁcant peripheral edema, impaired hepatic or renal function,
ongoing steroid therapy, malignancy, known hypersensitivity to study drugs, or
history of alcohol abuse or mental disorder were excluded from the study.
Pregnant and lactating women were also excluded from the study. In addition,
randomizing a small group of on-statin patients was also planned in a separate
arm of the study. However, execution of this planwas discontinued later because
of logistic reasons and also because such a randomization was not the primary
objective of the study (Fig. 1).
Study procedures
After enrolment, all participants underwent a general physical examina-
tion, 12-lead electrocardiogram, routine microscopic urine examination, and
biochemical investigations including complete blood count, fasting lipid proﬁle
(total cholesterol [TC], LDL-C, high-density lipoprotein cholesterol [HDL-C],
serum triglyceride), glycosylated hemoglobin, renal function tests (blood urea
nitrogen, total bilirubin, and serum creatinine), and liver function tests (alanine
transaminase, aspartate transaminase, and alkaline phosphatase). Blood sam-
ples were collected after an overnight fast for 8 to 12 h. All laboratory in-
vestigations were performed at a centralized facility (SRL Diagnostics, www.srl.
in).
After baseline assessments, each subject was assigned a unique subject
number. On the randomization visit, the eligible subjects received one sealed
envelope containing information regarding the subject number on the front and
bottle number on the inner side of the envelope. The subjects were randomly
assigned in a 1:1 ratio using these sealed envelopes to receive either RYR-NS,
600-mg capsule twice a day (n ¼ 96) or a matching placebo (n ¼ 95), which
was administered for 12 wk in a double-blinded manner. All subjects were also
advised lifestyle modiﬁcations and healthy diets by a certiﬁed dietitian according
to their health status.
At 4 wk (4 d) of study treatment, the subjects visited the trial site for clinical
evaluation and blood collection for determining LDL-C and TC levels. Vital pa-
rameters were assessed and history was obtained about any possible adverse
events for all the patients. Compliance with the study treatment was conﬁrmed
by questioning the subjects and collecting used bottles of the study medication
before dispensing new bottles of RYR-NS or placebo capsules for the remaining
study duration. The participants were also verbally questioned about theirRYR-NS (n ¼ 92) Placebo (n ¼ 88) P-value
47.0  9.7 47.4  10.4 0.77
58 (63.0%) 45 (51.1%) 0.11
67.3  11.5 69.6  13.0 0.21
31 (33.7) 32 (36.4) 0.71
25.5  4.2 26.8  4.7 0.06
220.3  32.4 (5.71  0.84) 221.2  28.8 (5.73  0.75) 0.85
146.7  22.8 (3.80  0.59) 149.3  21.5 (3.87  0.56) 0.42
42.1  9.1 (1.09  0.24) 40.0  8.1 (1.04  0.21) 0.10
178.2  30.9 (4.62  0.80) 181.3  28.4 (4.70  0.74) 0.50
163.0  74.8 (1.84  0.85) 180.5  67.1 (2.04  0.76) 0.10
6.3  1.5 6.4  1.6 0.59
10.8  3.5 10.8  3.2 0.98
0.9  0.2 0.9  0.2 0.58
0.56  0.26 0.46  0.22 0.01
48.1  25.2 44.0  16.7 0.19
30.1  30.3 24.7  9.5 0.10
94.0  20.6 94.9  24.9 0.79
4 (4.3) 1 (1.1)
1 (1.1) 2 (2.3)
3 (3.3) 6 (6.8)
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R. R. Kasliwal et al. / Nutrition 32 (2016) 767–776770adherence to lifestyle measures, including diet, and were counselled once again
about the same.
At 12 wk (4 days), all subjects underwent the same evaluations as at
baseline. In addition, a detailed history about any adverse events that may have
occurred since the last visit was also obtained.
Outcome measures
Primary efﬁcacy outcome measures were absolute and percent change in
LDL-C levels at wk 4 and 12. In addition, data were analyzed to determine the
effect of RYR-NS on the following additional efﬁcacy measures:
 Absolute and percent change in TC, triglyceride, HDL-C, and non-HDL-C
levels at wk 12.
 Number of patients achieving desirable or above desirable levels of LDL-C
and non-HDL-C, as per the 2014 U.S. National Lipid Association recom-
mendations [30].
Primary safety measures were changes in renal and liver function param-
eters at wk 12, whereas the change in HbA1c at wk 12 was a secondary safety
measure. In addition, the incidence and severity of adverse events was also
recorded.
Statistical analysis
Standard descriptive analyses were performed to summarize the study
parameters. All values are expressed as mean standard deviation or as counts
and percentages. Baseline parameters in the two groups were compared using
Student’s independent samples t test or chi-square test as appropriate. Changes
in quantitative parameters from baseline within each group were assessed
using paired t test or repeated measures analysis of variance. Repeatedmeasure
modeling was also performed to evaluate the overall treatment effect on these
parameters. McNemar test was used for evaluating changes in qualitative
parameters. All statistical analyses were performed using the SAS statistical
package, version 9.1 (SAS Institute Inc, Cary, NC, USA). A P-value of <0.05 was
considered statistically signiﬁcant.
Sample size estimation
Assuming an average standard deviation of 30 mg/dL (0.78 mmol/L) for
LDL-C in the two groups, 72 subjects were required in each group to detect a
postintervention difference of 15 mg/dL (0.39 mmol/L) with 85% power.
Allowing a 20% drop-out rate, we included at least 90 subjects in each group.
Results
Baseline data
A total of 337 subjects were screened, out of which 191
subjects satisfying eligibility criteria were randomized to
receive RYR-NS (96 subjects) or placebo (95 subjects). Of these,
11 patients (four in the RYR-NS group and seven in the placebo
group) withdrew from the study, citing their unwillingness to
continue their participation in a research project. The remain-
ing 180 patients who completed the study were included in the
analysis (Fig. 1).
The mean age of the subjects was 47.2  10.0 y and 57% (103
of 180 subjects) were males. Sixty-three subjects (35.0%) had
diabetes. Although the serum bilirubin level was slightly higher
in the RYR-NS group (0.6 0.3mg/dL versus 0.5 0.2 mg/dL for
placebo, P ¼ 0.01), there were no other signiﬁcant differences
between the two groups at baseline (Table 1). None of the
participants were on any lipid lowering therapy (apart from the
study formulation) and the use of other concomitant medica-
tions was also very infrequent.
Primary efﬁcacy outcomes
Treatment with RYR-NS resulted in a signiﬁcant reduction in
LDL-C levels from 146.7  22.8 mg/dL (3.80  0.59 mmol/L) at
baseline to 113.5  30.1 mg/dL (2.94  0.78 mmol/L) at wk 4
and 102.6  31.2 mg/dL (2.66  0.81 mmol/L) at wk 12
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Fig. 2. Mean lipid levels in the two groups during the study period. All values represent mean with 95% conﬁdence intervals. To convert to mmol/L, multiply by 0.0259 for
cholesterol and 0.0113 for triglyceride. P-value is for overall comparison between the two groups and reﬂects time  treatment interaction.
R. R. Kasliwal et al. / Nutrition 32 (2016) 767–776 771(P < 0.0001 for trend) (Table 2, Fig. 2). This translated into 22%
reduction in LDL-C levels at wk 4 and 29% at wk 12 (Fig. 3). These
changes were signiﬁcantly greater than those observed in the
placebo group (6.7% and 3.5% reduction at wk 4 and 12 respec-
tively; all P values < 0.001 for comparisons with the RYR-NS
group).
Additional efﬁcacy outcomes
RYR-NS resulted in signiﬁcant reductions from baseline to wk
12 in the levels of TC (220.3 32.4mg/dL [5.710.84mmol/L] to
168.4  34.8 mg/dL [4.36  0.90 mmol/L], 22.7%, P < 0.0001),
non-HDL-C (178.2  30.9 mg/dL [4.62  0.80 mmol/L] to
123.5  33.4 mg/dL [3.20  0.87 mmol/L], 29.8%, P < 0.001),
and triglyceride (163.0  74.8 mg/dL [1.84  0.85 mmol/L] to
139.0  79.6 mg/dL [1.57  0.90 mmol/L], 4.5%, P ¼ 0.01)
(Table 2, Figs. 2 and 3), whereas HDL-C levels increased from
42.1  9.1 mg/dL (1.09  0.24 mmol/L) to 46.1  14.7 mg/dL
(1.19  0.38 mmol/L), (þ9.5%, P ¼ 0.01). Participants randomized
to receive placebo also experienced reductions in TC and
non-HDL-C levels (6.7% and 10.3%, respectively) but these
changes were signiﬁcantly lower than those observed in the
RYR-NS group (both P < 0.0001).
At baseline, only 20.7% patients in the RYR-NS group had LDL-
C levels in the desirable (<100 mg/dL/2.59 mmol/L) or above
desirable (100–129 mg/dL/2.59–3.34 mmol/L) categories as per
the U.S. National Lipid Association recommendations [30].However, by the end of wk 12, this percentage increased to 84.8%
(P < 0.0001) with only 15.2% patients having borderline high
(130–159 mg/dL or 3.37–4.12 mmol/L), high (160–189 mg/dL or
4.14–4.90 mmol/L), or very high (190 mg/dL or 4.92 mmol/L)
LDL-C levels (Fig. 4). In contrast, 14.8% patients had desirable or
above desirable LDL-C levels at baseline in the placebo group,
and this proportion increased to only 27.3% by the end of wk 12.
Similarly, 39.1% patients in the RYR-NS group had desirable
(<130mg/dL or 3.37mmol/L) or above desirable (130–159mg/dL
or 3.37–4.12 mmol/L) non-HDL-C levels at baseline, which
increased to 87.0% at wk 12 (P < 0.0001). In the placebo group,
the percentage of such patients increased from 23.9% at baseline
to only 44.3% at the end of wk 12.
Safety and tolerability
RYR-NS was well tolerated during the 12 wk of treatment
period and no study drug discontinuations occurred in any of the
two groups. There were no clinically relevant changes in any of
the safety parameters during the course of the study (Table 3).
However, RYR-NS patients showed a small but statistically sig-
niﬁcant (P ¼ 0.027) decline in alanine transaminase levels from
48.125.2 U/L at baseline to 42.415.8 U/L, at wk 12 (P¼ 0.035;
P ¼ 0.027 for comparison with placebo) whereas total bilirubin
level increased slightly in the placebo group from
0.46  0.22 mg/dL to 0.51  0.21 mg/dL (P ¼ 0.028; P ¼ 0.08 for
comparison with the RYR-NS group). In the context of the
p
ri
n
t
&
w
e
b
4
C
=
F
P
O
Fig. 3. Percent changes in various lipid parameters in the two groups during the study period. All values represent mean with 95% conﬁdence intervals.
R. R. Kasliwal et al. / Nutrition 32 (2016) 767–776772present study, these changes appear to be a result of the phe-
nomenon of regression to the mean rather than of any actual
change in liver functions.
Adverse events were very infrequent (gastric acidity/
discomfort: RYR-NS 2, placebo 2; diarrhea/vomiting: RYR-NS 3,
placebo 0; fatigability/body aches: RYR-NS 0, placebo 4) and
were similar in the two groups (overall P ¼ 0.91). All adverse
events were transient and none was severe. All adverse events
were unrelated to the study treatment with the exception of one
treatment-related event of gastric acidity in the placebo group.Discussion
This was the ﬁrst randomized double-blind placebo-
controlled study evaluating lipid lowering efﬁcacy and short-
term safety proﬁle of a bioactive phytonutrient formulation in
a primary prevention setting in India. We found that a 12-wk
treatment with RYR-NS resulted in nearly 30% reduction in
LDL-C and non-HDL-C levels, which is comparable with re-
ductions seen with moderate-intensity statin therapy [31].Additionally, no safety concerns were encountered with RYR-NS
during the 12-wk treatment period.Lipid-lowering efﬁcacy and the mechanisms of action of RYR-NS
RYR-NS consists of a mixture of food-derived bioactive in-
gredients (Appendix A) with distinct pharmacologic activities
and can be standardized for predictable results. The qualitative
and quantitative rationale for combining the speciﬁc ingredients
in double zero vegetarian capsules with twice-daily dosing is
proprietary to the investigational product, RYR-NS. The use of
each ingredient in the combination is based on complementary
and synergistic mechanisms of action in lipid metabolism and
inﬂammatory pathways, bioavailability, and, importantly, sta-
bility in harsh weather conditions, which is common to low-
income countries of the world.
RYR powder, which is the key ingredient, contains a milieu of
monacolins, some of which are natural inhibitors of hydrox-
ymethylglutarylcoenzyme A reductase, an enzyme also inhibited
by statins. The lipid-lowering efﬁcacy and safety of RYR has been
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Fig. 4. Treatment effect on patient distribution in various lipid categories as per
National Lipid Association recommendations. Please see text for further details.
R. R. Kasliwal et al. / Nutrition 32 (2016) 767–776 773evaluated in previous studies [21–24]. Of these, the only large
study on RYR randomized 4870 participants to placebo or
Xuezhikang, a partially puriﬁed extract of RYR. After a meanTable 3
Effect of treatment with RYR-NS on safety parameters
Safety parameters RYR-NS
Baseline 12 wk P-va
Body mass index, kg/m2 25.5  4.2 25.5  4.3 0.36
Glycosylated hemoglobin, % 6.3  1.5 6.2  1.6 0.43
Blood urea nitrogen, mg/dL 10.8  3.5 11.1  5.8 0.65
Serum creatinine, mg/dL 0.9  0.2 1.0  0.4 0.18
Total bilirubin, mg/dL 0.56  0.26 0.54  0.31 0.54
Alanine transaminase, U/L 48.1  25.2 42.4  15.8 0.03
Aspartate transaminase, U/L 30.1  30.34 26.2  15.46 0.27
Alkaline phosphatase, U/L 94.0  20.6 95.7  25.8 0.55
All values are mean  standard deviation
* P-value is for overall comparison between the two groups.follow-up for 4.5 y, treatment with Xuezhikang resulted in 45%
reduction in the incidence of major adverse CV events [23]. Most
of the other studies with RYR have been small but have consis-
tently demonstrated its LDL-C-lowering efﬁcacy [21]. RYR has
also been evaluated in patients with statin intolerance. Becker
et al. randomized 62 patients with dyslipidemia and a history of
discontinuation of statin therapy because of myalgias to RYR or
placebo for 24 wk [22]. RYR not only resulted in signiﬁcant
lowering of LDL-C, TC, and triglyceride levels, there was no in-
crease in creatine phosphokinase levels and only two patients
complained of myalgias as compared to one patient in the pla-
cebo group. Based on these published reports, the European Food
Safety Authority has approved RYR as a food for maintenance of
normal cholesterol levels [32]. However, RYR has heretofore
never been tested in Indian subjects.
Other ingredients of RYR-NS also have beneﬁcial lipid
lowering or vascular effects. While niacin is known to increase
HDL-C and lower LDL-C levels, folic acid reduces elevated ho-
mocysteine levels [25,26]. Grapeseed extract has antioxidant
properties and may also lower LDL-C [27]. Black pepper seed
powder (active principle, piperine) also has antioxidant effects
and increases the bioavailability of various nutrients through a
number of mechanisms [33].
However, for any combination of food-derived ingredients, the
exact preparation needs to be tested independently for its efﬁcacy
and safety because of unknown interactions among different in-
gredients. In our study, the reduction in LDL-C levels achievedwith
RYR-NS was more than what has been demonstrated with RYR
alone. This indicates a possible synergistic action between RYR and
other ingredients of RYR-NS, especially niacin, folic acid, grape seed
and black pepper seed powder. More importantly, despite a greater
LDL-C-lowering effect, RYR-NSwas not associatedwith any adverse
events during the study period.
Clinical relevance of the ﬁndings
Statins are currently the most effective agents available for
managing dyslipidemia and have been shown to reduce CV
events in a wide variety of patient populations [10,25,31].
Accordingly, statins are the agents of choice in most patients
requiring lipid-lowering therapy. However, it has been observed
that even in those adequately treated with statins, the absolute
risk of CV events remains high despite a signiﬁcant relative risk
reduction [5,8,9]. The pursuit to understand the mechanisms
responsible for this high residual CV risk in statin-treated in-
dividuals has led to newer insights into the lipid-atherosclerosis
relationship. Recent studies using non-statin therapies such as
ezetimibe or proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors have shown that the residual CV risk can bePlacebo P-value*
lue Baseline 12 wk P-value
26.8  4.7 26.8  4.7 0.31 0.32
6.4  1.6 6.3  1.5 0.29 0.70
10.8  3.2 10.7  5.2 0.86 0.66
0.9  0.2 0.9  0.3 0.28 0.48
0.46  0.22 0.51  0.21 0.028 0.08
5 44.0  16.7 45.2  17.9 0.43 0.027
24.7  9.5 25.7  10.25 0.36 0.18
94.9  24.9 97.7  30.3 0.33 0.77
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34–37]. At the same time, it has become increasingly evident
now that not only the magnitude of LDL-C lowering is important
but that the duration of exposure to elevated LDL-C levels is
equally important [11,16,38]. Since atherosclerosis begins during
childhood, initiating even moderate LDL-C lowering at an early
stage of life can result in substantial reduction in the lifetime
CVD risk. In contrast, lowering LDL-C levels when atherosclerosis
has already become clinically overt may serve merely to stabilize
existing plaques that can still progress to cause symptoms or
disrupt to cause acute coronary syndromes, thus resulting in a
high residual risk of events. The exceptionally low rates of CV
events observed in patients carryingmutations in PCSK9 or other
similar genes despite only modestly low LDL-C levels strongly
support this notion [11]. Similar ﬁndings have also shown by
Ference et al. in a large metaanalysis evaluating the impact of
nine polymorphisms in six different genes involved in LDL-C
metabolism [13]. It was found that lifelong exposure to low
LDL-C levels as a result of these gene polymorphisms was asso-
ciated with three-fold greater reduction in the risk of CVD per
unit lower LDL-C level than that observed during treatment with
a statin started later in life. These evidences clearly suggest that a
primary prevention strategy that encourages maintaining low
levels of LDL-C throughout one’s lifetime has the potential to
dramatically reduce the risk of CVD.
However, despite these encouraging evidences, it is not
known how best to achieve effective LDL-C lowering from an
early age. While adopting healthy lifestyle behaviors is certainly
helpful and must be encouraged, it alone is not sufﬁciently
effective because of general apathy toward these measures, as
documented in the PURE (Prospective Urban Rural Epidemi-
ology) study [39]. Although statins may be an effective option,
they are limited by variable and largely poor uptake, with less
than 5% of patients with CVD shown to be on regular statin
therapy in low- and lower-middle-income countries [20]. The
usage of statins in primary prevention settings is even lower,
even in developed countries, where a vast majority of the
patients are not on regular statin therapy [40]. The concerns of
adverse effects and inherent psychological barrier against the
lifetime use of a drug are amongst the major reasons responsible
for such a low uptake of proven drugs like statins. These obser-
vations are corroborated by the PURE study data showing much
lower usage of proven medical therapies by younger individuals
as compared to older subjects [20]. Under these circumstances,
the availability of a food-based therapeutic solution that appeals
to the social and cultural sensibilities of the people from coun-
tries like India, China, and others where traditional medicine
systems coexist could be very beneﬁcial. If proven safe and
effective, such a formulation could help improve lipid levels
in these communities through potentially better adherence to
these agents as compared to statin therapy. A functional food/
bioactive phytonutrient formulation could also be potentially
helpful in cases of actual statin intolerance [41] or when statins
alone are not able to bring about desired LDL-C reduction, as
there is currently lack of effective pharmacologic options that
could be used either in place of or in combination with statin
therapy.
Several food-based lipid lowering therapies have been tried
in the past, showing variable results. For example, a metaanalysis
of studies evaluating the role of spirulina supplementation
documented signiﬁcant LDL-C lowering effect [42], whereas no
such changes were observed with other agents such as garlic and
astaxanthin [43,44]. In the present study, we used RYR-NS and
observed a signiﬁcant LDL-C lowering effect. Importantly, whilenone of the patients had LDL-C levels within desirable limits at
baseline, the proportion increased to 43.4% with just 12 wk of
treatment with RYR-NS. The impact on non-HDL-C levels was
even greater with 55.4% of the subjects reaching desirable levels
as compared to just 1.1% at the baseline. Substantial public health
gains can bemade if these reductions could be sustained over the
long term. As part of ESSENS, large-scale, long-term studies are
already being conceptualized to evaluate the impact of RYR-NS
on clinical outcomes.
Limitations
The main limitations of the present study included its rela-
tively small sample size and short duration. As a result, it was not
possible to determine the long-term safety of RYR-NS. However,
while there is a need for a large, long-term, prospective, clinical
study to evaluate the efﬁcacy and safety of RYR-NS, it must be
noted that the safety and efﬁcacy of various food-derived in-
gredients of RYR-NS have already been evaluated in a number of
small- and large-scale studies [21–24]. In fact, as outlined earlier,
RYR has also been evaluated and found to be safe in a small group
of statin intolerant patients. These results are reassuring since
most of the side effects of various lipid lowering therapies, with
the notable exception of statin-induced diabetes, are observed
mainly during the initial few weeks of treatment.
The other major limitation of the present study was that only
statin free patients were included. As a result, it could not be
assessed whether RYR-NS could result in incremental reduction
in LDL-C levels in patients already on statin therapy. Further
studies are required to address this issue.
Conclusion
This study demonstrates the efﬁcacy and safety of RYR-NS in
LDL-C and non-HDL-C lowering after 12 wk of treatment in In-
dians. A nearly 30% reduction in LDL-C levels observed at wk 12
with RYR-NS is comparable to reductions seen with moderate-
intensity statin therapy. There were no safety/tolerability issues
observedwith RYR-NS. Further large-scale, long-term studies are
being conceptualized to determine the impact of RYR-NS on
treatment adherence, and thus, on clinical outcomes.
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Appendix A
Composition details of the study formulation RYR-NS
Scientiﬁc name of ingredients: The Latin binomial name and common name Consists of a combination blend of following food-derived ingredients:
1. Red yeast rice powder (Monascus purpureus)
2. Grape seed extract powder (Vitis vinifera)
3. Black pepper seed extract powder- (Piper nigrum)
4. Niacinamide (Niacin)
5. Vitamin B9 (Folic Acid)
Manufacturer and brand name: The proprietary product name (i.e., brand name)
and the name of the manufacturer
Manufacturer: PreEmptive Meds, Inc. USA
Brand Name: PreLipid
Ingredient extraction/manufacturing: The part(s) of plant or botanical used to
produce the product or extract & solvent used
1. Red yeast rice (Rice powder). No solvent used
2. Grape seed powder (Seeds). Water based solvent
3. Black pepper powder- (Seeds) Water based solvent
4. Niacinamide (Niacin) (Synthetic)
5. Vitamin B9 (Folic Acid) (Synthetic)
Serving size: The dosage of the product, and how these were determined 1. 600 mg twice-a-day in double-zero size Hydroxy Propyl Methyl
Cellulose (HPMC) opaque red color capsules (Vegetarian, kosher
& halal certiﬁed)
2. How dosage and duration is determined: Twice-daily dosage
(one capsule in the morning and one at night) was based on
half-life of food-based ingredients; quantity of standardized
actives in each ingredient and based on proprietary knowledge
gained from US clinical experience of eight years
Dosage: The content (e.g., as weight) of all ingredients and added materials 1. Red yeast rice powder: 400 mg;
2. Grape seed extract powder: 35 mg;
3. Black pepper powder: 10 mg;
4. Niacinamide: 7 mg;
5. Vitamin B9: 100 mcg;
6. Excipients (starch, magnesium stearate) 100 mg
Placebo: The rationale for the type of control or placebo used As the study was double-blinded, the placebo capsule used was double
zero HPMC opaque red capsules and ﬁlled with 600 mg of maize starch.
Appendix B. Participating sites
1. Medanta- The Medicity, Gurgaon, Delhi NCR, India.
2. Fortis Escorts Hospital, Jaipur, Rajasthan, India.
3. Pai Research Center, Pune, Maharashtra, India.
4. Bhatia Hospital, Mumbai, Maharashtra, India.
5. Lifecare Hospital, Ahmedabad, Gujarat, India.
6. Apollo Hospital, Chennai, Tamil Nadu, India.
7. Singhvi Health Center, Chennai, Tamil Nadu, India.
8. Pace Research Center, Bangalore, Karnataka, India.
9. Pruthvi Heart Center, Ahmedabad, Gujarat, India.
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